A peer-reviewed version of this preprint was published in PeerJ on 30 April 2015.

View the peer-reviewed version (peerj.com/articles/903), which is the preferred citable publication unless you specifically need to cite this preprint.

Temporal changes in nasopharyngeal carriage of Streptococcus pneumoniae serotype 1 genotypes in healthy Gambians before and after the 7-valent pneumococcal conjugate vaccine

Streptococcus pneumoniae serotype 1 is one of the leading causes of invasive pneumococcal disease. However this invasive serotype is hardly found in nasopharyngeal asymptomatic carriage and therefore large epidemiological studies are needed to assess the dynamics of serotype 1 infection. Within the context of a large cluster randomized trial conducted in rural Gambia to assess the impact of PCV-7 vaccination on nasopharyngeal carriage, we present an ancillary study describing the prevalence of nasopharyngeal carriage of pneumococcal serotype 1 and temporal changes of its more frequent genotypes.

Nasopharyngeal swabs (NPS) were collected before PCV-7 vaccination (December 2003-May 2004) and up to 30 months after PCV-7 vaccination (post-vaccination periods 1 to 3: July 2006 – March 2007; April 2007 – March 2008 and April 2008 – Feb 2009). S. pneumoniae serotype 1 were genotyped by MLST.

Serotype 1 was recovered from 87 (0.71%) of 12,319 NPS samples collected. In the pre-vaccination period, prevalence of serotype 1 was 0.47% in both study arms. In the post-vaccination periods, prevalence in the fully vaccinated villages ranged between 0.08% in period 1 and 0.165% in period 2; while prevalence in partly vaccinated villages was between 0.17% in period 3 and 1.34% in period 2. Overall four different genotypes were obtained with ST3081 the most prevalent (60.71%) followed by ST618 929.76%). ST3081 was found only in post-vaccination period 2 and 3 while ST618 had disappeared in post-vaccination period 3. Distribution of these major genotypes was similar in both study arms.
Emergence of ST3081 and concomitant disappearance of ST618 may suggest a change in the molecular epidemiology of pneumococcal serotype 1 in this region. This change is not likely to be associated with the introduction of PCV-7 which lacks serotype 1 as it was observed simultaneously in both study arms. Future population-based epidemiological studies will provide further evidence of substantive changes in the pneumococcal serotype 1 epidemiology and the likely mechanisms.
Temporal changes in nasopharyngeal carriage of *Streptococcus pneumoniae* serotype 1 genotypes in healthy Gambians before and after the 7-valent pneumococcal conjugate vaccine

*Streptococcus pneumoniae* serotype 1 is one of the leading causes of invasive pneumococcal disease. However this invasive serotype is hardly found in nasopharyngeal asymptomatic carriage and therefore large epidemiological studies are needed to assess the dynamics of serotype 1 infection. Within the context of a large cluster randomized trial conducted in rural Gambia to assess the impact of PCV-7 vaccination on nasopharyngeal carriage, we present an ancillary study describing the prevalence of nasopharyngeal carriage of pneumococcal serotype 1 and temporal changes of its more frequent genotypes.

Nasopharyngeal swabs (NPS) were collected before PCV-7 vaccination (December 2003–May 2004) and up to 30 months after PCV-7 vaccination (post-vaccination periods 1 to 3: July 2006 – March 2007; April 2007 – March 2008 and April 2008 – Feb 2009). *S. pneumoniae* serotype 1 were genotyped by MLST.

Serotype 1 was recovered from 87 (0.71%) of 12,319 NPS samples collected. In the pre-vaccination period, prevalence of serotype 1 was 0.47% in both study arms. In the post-vaccination periods, prevalence in the fully vaccinated villages ranged between 0.08% in period 1 and 0.165% in period 2; while prevalence in partly vaccinated villages was between 0.17% in
period 3 and 1.34% in period 2. Overall four different genotypes were obtained with ST3081 the
most prevalent (60.71%) followed by ST618 929.76%). ST3081 was found only in post-
vaccination period 2 and 3 while ST618 had disappeared in post-vaccination period 3.
Distribution of these major genotypes was similar in both study arms.
Emergence of ST3081 and concomitant disappearance of ST618 may suggest a change in the
molecular epidemiology of pneumococcal serotype 1 in this region. This change is not likely to
be associated with the introduction of PCV-7 which lacks serotype 1 as it was observed
simultaneously in both study arms. Future population-based epidemiological studies will provide
further evidence of substantive changes in the pneumococcal serotype 1 epidemiology and the
likely mechanisms.
Temporal changes in nasopharyngeal carriage of

*Streptococcus pneumoniae* serotype 1 genotypes in healthy

Gambians before and after the 7-valent pneumococcal

conjugate vaccine

Chinelo Ebruke¹,²

Anna Roca¹

Uzochukwu Egere¹

Ousainou Darboe¹

Philip C Hill³

Brian Greenwood²

Brendan W. Wren²

Richard A Adegbola¹,⁴

Martin Antonio¹,²,⁵,*

¹Vaccinology Theme, Medical Research Council Unit, Banjul, The Gambia

²Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom

³Centre for International Health, School of Medicine, University of Otago, New Zealand

⁴GlaxoSmithKline Biologicals Wavre, Belgium

⁵Microbiology and Infection Unit, Warwick Medical School, University of Warwick, Coventry, United Kingdom
For corresponding author email: mantonio@mrc.gm
Introduction

Streptococcus pneumoniae is usually found in the nasopharynx of healthy individuals which is considered a necessary step preceding invasive pneumococcal disease (IPD), including pneumonia, meningitis, and bacteraemia (Gleich, Morad et al. 2000, Bogaert, De Groot et al. 2004, Baker, Barrozo et al. 2005, Adegbola, Hill et al. 2006, Hill, Akisanya et al. 2006, Ahern and Raszka 2009, Balicer, Zarka et al. 2010). There are over 90 different S. pneumoniae serotypes of which serotype 1 is a common cause of IPD worldwide with particular high rates of disease in sub-Saharan Africa (Hausdorff, Bryant et al. 2000, Adegbola, Hill et al. 2006, Gessner, Mueller et al. 2010).

As cases of invasive disease represent only a small fraction of the pneumococcal burden, there is an increasing interest on evaluating the prevalence of pneumococcal asymptomatic carriage in the nasopharynx, since this is important in understanding the dynamics of disease and transmission as well as providing a basis for assessing the impact of interventions (Bogaert, De Groot et al. 2004). Interestingly, serotype 1 is rarely found in the nasopharynx of healthy individuals (Hill, Akisanya et al. 2006, Laval, de Andrade et al. 2006, Antonio, Hakeem et al. 2008, Nunes, Sa-Leao et al. 2008). As a result, there are just few studies evaluating the dynamics of serotype 1 in nasopharyngeal carriage as large epidemiological studies are needed.

Although PCV-7, the first licensed pneumococcal vaccine, did not include serotype 1 in its formulation new PCV licensed vaccines (PCV-10 and PCV-13) include this serotype and therefore, understanding the dynamics of serotype 1 carriage has become a priority. Within the context of a cluster-randomized trial conducted in rural Gambia (Roca, Hill et al. 2011), we
collected a large number of NPS (12, 319 samples) before and up to 30 months after starting the
trial (Hill, Akisanya et al. 2006, Roca, Hill et al. 2011). As an ancillary study of the trial, we
describe the dynamics of pneumococcal serotype 1 nasopharyngeal carriage within a period of 6
years before and after the PCV-7 trial.

Materials and Methods

Study design and collection of isolates

This study was an ancillary study of large pneumococcal carriage studies conducted in 21
selected villages in rural Gambia as previously described (Hill, Akisanya et al. 2006, Roca, Hill
et al. 2011). Firstly, a pre-vaccination cross sectional survey was conducted between December
2003 and May 2004 in which NP samples were collected from subjects of all age groups (Hill,
Akisanya et al. 2006). Following this, a single-blind, cluster-randomized (by village) trial to
evaluate the impact of PCV-7 on pneumococcal carriage was conducted in the study villages
(Roca, Hill et al. 2011). In one group of 11 villages, all individuals over the age of 30 months
received one dose of PCV-7 whilst subjects in this age group resident in 10 control villages
received one dose of serogroup C meningococcal conjugate vaccine. All children less than 30
months of age in both study groups and infants born during the course of the trial received PCV-
7. The trial showed a marked decrease of nasopharyngeal carriage of vaccine type (VT)
pneumococci in all age groups and both study arms with a more marked drop in villages where
the whole community had received PCV-7 (Roca, Hill et al. 2011). There was little change in the
overall prevalence of NVT carriage following introduction of the vaccine (Roca, Hill et al.
2011).
NP swabs were collected during an initial pre-vaccination cross-sectional survey (CSS) and during cross-sectional surveys conducted from 4 to 30 months after vaccination (Table 1) (Roca, Hill et al. 2011) and during a longitudinal study (unpublished data). For the purposes of this analysis, post-vaccination data are shown for three different time-periods (Table 1).

Approval for this study was obtained from the Joint Medical Research Council (MRC)/Gambia Government Ethics Committee and the Ethics Committee of the London School of Hygiene & Tropical Medicine, UK. The conduct of the trial was guided by a Data Safety and Monitoring Board and community and individual consent was obtained from study participants.

**Serotyping and multi locus sequence typing (MLST)**

A total of 87 *S. pneumoniae* serotype 1 isolates obtained from NP swabs during a survey were identified by latex agglutination (Hill, Akisanya et al. 2006) and confirmed by molecular serotyping (Morais, Carvalho Mda et al. 2007). Multi locus sequence typing was performed on viable *S. pneumoniae* serotype 1 isolates recovered after storage at -70°C as previously described (Antonio, Hakeem et al. 2008).

**Data analysis**

All statistical analysis were carried out in STATA (version 11, Stata m Corporation, College Station TX) using Chi-square tests. *p*-Values less than 0.05 were taken to indicate statistical significance. Sequences were edited and aligned using the Laser Gene DNA star 7.1 software. Sequence type (ST) was obtained by submission of sequences onto the MLST database website. STs were analyzed for relatedness using the eBURST v3 program.
Results

A total of 12,319 NP samples were collected during the study; 22.2% of which were from the pre-vaccination period and 32.4%, 28.2% and 17.2% from the post-vaccination study periods 1 to 3 respectively. The median age of sampled individuals was 15 years (IQR 5.9 - 45 years), 11 years (IQR 4.7 - 29 years), 11 years (IQR 5.6 - 27 years) and 14 years (IQR 6.7 - 33 years), in the pre-vaccination and post vaccination periods 1 to 3 respectively. The overall prevalence of S. pneumoniae in the pre-vaccination period was 71.78% (1,971 out of 2,746 samples). The overall prevalence of S. pneumoniae in the post-vaccination periods 1 to 3 was 47.08% (4,507 out of 9,573 samples).

The overall prevalence of S. pneumoniae serotype 1 was 0.71% (87 of 12,319 samples collected). Prevalence of serotype 1 carriage was highest (1.02%) among children aged 5 to 14 years (p<0.001) compared to other age groups and in post-vaccination period 2 (1.50%) compared to the other study periods (p<0.001) (Table 1).

The overall prevalence of serotype 1 pneumococcal carriage was similar in vaccinated and control villages (0.73% versus 0.68%; p=0.703). In the pre-vaccination study period, prevalence of carriage of serotype 1 was the same in both vaccinated and control villages (0.47% each). However, the prevalence was lower in vaccinated than in control villages in post-vaccination period 1 (0.08% vs. 0.48%, p=0.011), similar in vaccinated and control villages in period 2 (1.65% vs. 1.34%, p= 0.459) and higher in vaccinated villages in period 3 (1.16% vs. 0.17%, p=0.004) (Table 2).
MLST analysis was performed for 84 of the 87 serotype 1 isolates obtained (97%). Four different STs were obtained with ST3081 being the predominant ST (60.71%) in both vaccinated and control villages followed by ST618 (29.76%), ST217 (7.14%) and ST303 (2.38%). Prevalence of different STs was not associated with age groups (p= 0.368). However, the distribution of STs differed over the course of the study (p<0.001). ST3081 was seen only in the post vaccination periods. ST618 was seen in the pre-vaccination and periods 1 and 2 post vaccination, but not in the post vaccination period 3 (Figure 1). Differences in the distribution of ST over the study periods was apparent in both vaccinated (p=0.002) and control (p=0.021) villages (Figure 2), with the observed expansion of ST3081 and the disappearance of ST618 occurring in both groups (Figures 1 & 2).

Discussion

Given that pneumococcal serotype 1 is one of the common cause of IPD worldwide and the paradox of its' rarity in nasopharyngeal carriage, it is not unsurprising that only a few published studies have evaluated serotype 1 carriage patterns. To our knowledge, this is the largest study evaluating the dynamics of pneumococcal serotype 1 carriage. We present findings from as many as 87 serotype 1 isolates and report on the prevalence and dominant genotype patterns over a 6 year period. The finding of 0.71% overall prevalence in carriage of serotype 1 agrees with earlier findings indicating the rarity of serotype 1 in carriage studies (Brueggemann and Spratt 2003, Hausdorff, Feikin et al. 2005, Laval, de Andrade et al. 2006, Nunes, Sa-Leao et al. 2008, Smith-Vaughan, Marsh et al. 2009) We note also that this low carriage rate was observed in both the
pre- and post vaccination periods with no significant differences between study arms. However, prevalence of serotype 1 carriage was highest in the age group 5-14 years. Findings from other studies suggest that this age group is at particular risk for serotype 1 IPD as opposed to other serotypes (Adegbola, Hill et al. 2006, Gessner, Mueller et al. 2010).

Introduction of the pneumococcal conjugate vaccine PCV-7 is associated with a reduction in carriage of VT serotypes but has also been linked to an increase in carriage of NVT in some settings (Mbelle, Huebner et al. 1999, Huang, Platt et al. 2005, O'Brien, Millar et al. 2007) but not in our setting (Roca, Hill et al. 2011) and elsewhere (Millar, Watt et al. 2008, Roca, Hill et al. 2011). In this study, serotype 1 prevalence showed variation over the study period but this is not likely to have been related to vaccine introduction as there was no consistent trend and no consistent difference between vaccinated and control villages. A higher carriage rate in the vaccinated group compared to the controls was observed in only one study period and a reverse picture was observed in another post vaccination period of the study. This pattern appears more likely to be due to natural variation over time rather than to an increase in NVT serotypes due to community vaccination with PCV-7.

All STs obtained in this study belong to the ST217 hyper virulent clonal complex responsible for several epidemic outbreaks in West Africa (Leimkugel, Adams Forgor et al. 2005, Yaro, Lourd et al. 2006, Antonio, Hakeem et al. 2008). The prevalence of the predominant serotype 1 genotypes (ST3081 and ST618) varied significantly over the study period. In period 3, we were unable to detect ST618, but noted instead the predominance of its quadruple locus variant ST3081. It is plausible that the changes between ST618 and ST3081 in this study population provides initial evidence of an expansion of the ST217 clonal complex, for which further studies
will provide more clarity. However, this finding could possibly have been due to temporal
temporal changes. We have also shown in our study area, the detection of a new sequence type in The
Gambia without evidence that this was associated with vaccination with PCV-7. Such emergence
of ST suggests natural variation in the molecular epidemiology of the pneumococcus that
requires further evaluation. A report from Brazil of a study that looked at invasive serotype 1
isolates over 3 decades found temporal changes in pulse field gel electrophoresis subtypes and
STs over time but the effect of pneumococcal vaccination was not evaluated (Chiou, Andrade et
al. 2008). This should be closely monitored in The Gambia in the near future as the wider PCV
formulation (PCV-13) has recently been introduced as part of the Expanded Programme of
Immunization.

However, we acknowledge some limitations with this study. Firstly, the samples in this study
were of modest size and a larger sample size would have allowed for more robust analysis
between the comparison groups. The modest number we got after sampling such a large
population goes to support the notion that serotype 1 is rare in carriage. Obtaining a much larger
sample size will therefore require very large epidemiological studies and its attendant challenges.
Secondly, this study was limited to carriage isolates from the Western division of The Gambia. It
is unclear if observations from this group are applicable to a more heterogeneous population.
There is therefore a need for further studies in The Gambia including population-based
molecular epidemiological studies assessing the distribution of these STs causing IPD and
whole-genome comparisons to identify genetic differences that could correspond with the
observed differences between otherwise highly similar strains and such studies are currently
underway.
Conclusions

In conclusion, we show in this study the prevalence of pneumococcal serotype 1 carriage as well as the predominant genotypes and how they varied over the study periods but this did not seem related to community vaccination with PCV-7. This provides important baseline data for further evaluation of nasopharyngeal carriage after PCV-13 has been introduced in The Gambia.

Abbreviations

IPD: Invasive Pneumococcal Disease; PCV-7: 7 valent pneumococcal conjugate vaccine; NPS: Nasopharyngeal Swab; MLST: Multilocus Sequence Typing; ST: Sequence type

Additional Information and Declarations

Competing Interests

The authors declare there are no competing interests.

Author Contributions

Chinelo Ebruke conceived and designed the experiments, performed the experiments, analyzed the data, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.

Anna Roca, Philip C Hill, Brian Greenwood, Brendan W. Wren and Richard A Adegbola conceived and designed the experiments, contributed reagents/materials/analysis tools, reviewed drafts of the paper.

Uzochukwu Egere and Ousainou Darboe contributed reagents/materials/analysis tools, reviewed drafts of the paper.

Martin Antonio conceived and designed the experiments, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.
Human Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

Approval for this study was obtained from the Joint Medical Research Council (MRC)/Gambia Government Ethics Committee and the Ethics Committee of the London School of Hygiene & Tropical Medicine, UK. The conduct of the trial was guided by a Data Safety and Monitoring Board and community and individual consent was obtained from study participants.

Funding

Support for Chinelo Ebruke’s PhD studentship and research costs was provided by the Medical Research Council Unit, The Gambia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

We would like to thank all the individuals who participated in the study. We also acknowledge the use of the core sequencing facility at MRC Unit, The Gambia and the S. pneumoniae MLST database which is housed at Imperial College, London, UK.
References


15


Figures:

Figure 1: Distribution of genotypes across study periods.

Figure 2: Distribution of genotypes across study periods in vaccinated and control villages.
### Table 1: Prevalence of nasopharyngeal pneumococcal serotype 1 carriage between pre-vaccination CSS and each of the post-vaccination cross sectional study.

<table>
<thead>
<tr>
<th>Study period</th>
<th>Number of NPS</th>
<th>Number of serotype 1 isolates (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-vaccination period</td>
<td>2746</td>
<td>13 (0.47)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>(December 2003- May 2004)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post vaccination Period 1</td>
<td>3986</td>
<td>9 (0.23)</td>
<td></td>
</tr>
<tr>
<td>(July 2006 – March 2007)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post vaccination Period 2</td>
<td>3469</td>
<td>52 (1.50)</td>
<td></td>
</tr>
<tr>
<td>(April 2007 – March 2008)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post vaccination Period 3</td>
<td>2118</td>
<td>13 (0.61)</td>
<td></td>
</tr>
<tr>
<td>(April 2008 - Feb 2009)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>12,319</td>
<td>87 (0.71)</td>
<td></td>
</tr>
</tbody>
</table>
Table 2: Prevalence of *nasopharyngeal pneumococcal* serotype 1 carriage between control and vaccinated villages in each cross sectional study.

<table>
<thead>
<tr>
<th>Study Period</th>
<th>Village Group</th>
<th>Number of NPS</th>
<th>Number of serotype 1 isolates (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-vaccination Period</td>
<td>Control</td>
<td>1271</td>
<td>6 (0.47)</td>
<td>0.992</td>
</tr>
<tr>
<td></td>
<td>Vaccinated</td>
<td>1475</td>
<td>7 (0.47)</td>
<td></td>
</tr>
<tr>
<td>Post vaccination Period 1</td>
<td>Control</td>
<td>1468</td>
<td>7 (0.48)</td>
<td>0.011</td>
</tr>
<tr>
<td></td>
<td>Vaccinated</td>
<td>2518</td>
<td>2 (0.08)</td>
<td></td>
</tr>
<tr>
<td>Post vaccination Period 2</td>
<td>Control</td>
<td>1711</td>
<td>23 (1.34)</td>
<td>0.459</td>
</tr>
<tr>
<td></td>
<td>Vaccinated</td>
<td>1758</td>
<td>29 (1.65)</td>
<td></td>
</tr>
<tr>
<td>Post vaccination Period 3</td>
<td>Control</td>
<td>1171</td>
<td>2 (0.17)</td>
<td>0.004</td>
</tr>
<tr>
<td></td>
<td>Vaccinated</td>
<td>947</td>
<td>11 (1.16)</td>
<td></td>
</tr>
</tbody>
</table>
Figure 1

![Graph showing prevalence over study periods]

- Baseline
- Period_1
- Period_2
- Period_3

Prevalence (%)

- Other STs
- ST3081
- ST618
Figure 2

**Controlled Villages**

- **Prevalence (%)**
- **Baseline**, **Period_1**, **Period_2**, **Period_3**
- **Other STs**
- **ST3081**
- **ST618**

**Vaccinated Villages**

- **Prevalence (%)**
- **Baseline**, **Period_1**, **Period_2**, **Period_3**
- **Other STs**
- **ST3081**
- **ST618**